HomeCompareBPMUF vs MO

BPMUF vs MO: Dividend Comparison 2026

BPMUF yields 2.82% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $53.8K in total portfolio value· pulled ahead in Year 5
10 years
BPMUF
BPMUF
● Live price
2.82%
Share price
$71.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.9K
Annual income
$337.79
Full BPMUF calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — BPMUF vs MO

📍 MO pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPMUFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPMUF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPMUF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPMUF
Annual income on $10K today (after 15% tax)
$239.44/yr
After 10yr DRIP, annual income (after tax)
$287.12/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, MO beats the other by $24,336.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPMUF + MO for your $10,000?

BPMUF: 50%MO: 50%
100% MO50/50100% BPMUF
Portfolio after 10yr
$50.8K
Annual income
$14,653.17/yr
Blended yield
28.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

BPMUF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.1
Piotroski
8/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPMUF buys
0
MO buys
0
No recent congressional trades found for BPMUF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPMUFMO
Forward yield2.82%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$23.9K$77.7K
Annual income after 10y$337.79$28,968.54
Total dividends collected$3.1K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: BPMUF vs MO ($10,000, DRIP)

YearBPMUF PortfolioBPMUF Income/yrMO PortfolioMO Income/yrGap
1$10,982$281.69$10,558$768.31+$424.00BPMUF
2$12,040$289.11$11,352$1,015.87+$688.00BPMUF
3$13,178$296.22$12,482$1,367.86+$696.00BPMUF
4$14,404$303.03$14,103$1,883.39+$301.00BPMUF
5← crossover$15,722$309.54$16,472$2,664.91$750.00MO
6$17,138$315.76$20,024$3,897.79$2.9KMO
7$18,659$321.69$25,537$5,933.74$6.9KMO
8$20,293$327.33$34,478$9,476.77$14.2KMO
9$22,046$332.70$49,776$16,022.63$27.7KMO
10$23,927$337.79$77,699$28,968.54$53.8KMO

BPMUF vs MO: Complete Analysis 2026

BPMUFStock

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

Full BPMUF Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this BPMUF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPMUF vs SCHDBPMUF vs JEPIBPMUF vs OBPMUF vs KOBPMUF vs MAINBPMUF vs PMBPMUF vs BTIBPMUF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.